Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 12/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541359 | 0.85 | QPCT (0.69) | QPCTKMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL22440185 | 0.81 | MAPT (0.54) | QPCTGAAPOLBMEN1KMT2A | |
| SCHEMBL2541690 | 0.80 | QPCT (0.54) | QPCTGAAPOLBMEN1KMT2A | |
| SCHEMBL2538430 | 0.80 | QPCT (0.67) | QPCTGAAALDH1A1MAPTKDM4E | |
| SCHEMBL21303609 | 0.80 | GAA (0.53) | QPCTGAAPOLBMEN1KMT2A | |
| SCHEMBL3630981 | 0.78 | QPCT (1.00) | QPCTALDH1A1 | |
| SCHEMBL2536231 | 0.78 | QPCT (0.67) | QPCTPOLB | |
| SCHEMBL2539376 | 0.78 | QPCT (0.67) | QPCTPOLBMAPTRAB9A | |
| SCHEMBL24821371 | 0.76 | ADRA2A (0.51) | QPCTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL18664376 | 0.75 | DHFR (0.58) | GAAPOLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885GAA 238/4885POLB 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.